Intimation of Analyst/Investor Meet

Event Type: Q2 and H1 FY27 Earnings Conference Call for Analysts and Investors, hosted by Avendus.

Date and Time: The call was held on Friday, November 06, 2026. A specific start time was not disclosed in the transcript.

Purpose: To discuss the company's operational and financial performance for the second quarter and first half of fiscal year 2027.

Earnings Announcement Timing: The call was a post-results discussion, held after the earnings were announced.

Management Participants:

  • Mr. Anil Satwani – Chairman and Managing Director
  • Mr. Raghavender Ramachandran – Chief Financial Officer
  • Mr. Shubham Saboo – Head of Complex Injectable Business and MDO
  • Mr. Kapil Mishra – Head of Strategy within the Chairman and Managing Director's Office
  • SGA, Investor Relation Advisor

The moderator was Mr. Harith Ahamed from Avendus.

Availability of Materials: The transcript of the call is available on the company's website at https://investor.symbiotec.com/financials?tab=transcripts. Audio recordings were also uploaded to the stock exchange on November 6, 2026, and are stated to prevail in case of any discrepancy with the transcript.

UPSI Statement: The document is a disclosure of the call's transcript and does not contain a specific statement regarding Unpublished Price Sensitive Information (UPSI).

Financial Highlights Discussed:

  • The discussion centered on Q2 FY27 and H1 FY27 results.
  • Q2 FY27 Consolidated Performance: Revenue stood at INR 280 crores, up 43% YoY. EBITDA was INR 94 crores, up 88% YoY (adjusted for one-time IPO expenses of INR 3 crores). PAT was INR 52 crores, up 169% YoY.
  • H1 FY27 Consolidated Performance: Revenue grew 25% YoY. EBITDA grew 29% YoY to INR 140 crores.
  • API Business Performance: Revenue was INR 227 crores in Q2, growing 16% YoY. H1 revenue grew 11% YoY. Gross margins were over 60% and EBITDA margins were stable at around 30%.
  • Milestone Revenue: INR 53 crores was recognized in Q2 from completed contractual milestones related to a new complex injectables agreement. This revenue is part of the consolidated figures.
  • Capex & Debt: Capex for H1 FY27 was INR 113 crores. Net debt as of September 30, 2026, was INR 314 crores.

Strategic and Forward-Looking Updates:

  • Complex Injectables (DCV): A long-term agreement was signed on September 30, 2026, with a leading global company for 2 products for the US market (addressable market ~USD 300 million). Revenue streams include development milestones, product supply revenue, and profit share. The first ANDA was filed in September 2026; a second is planned for Q4 FY27. Commercialization is expected in FY28. Development is also underway for a dual-chamber bag and a testosterone injectable CDMO.
  • Fermentation CDMO: A new 10-year take-or-pay agreement was signed with a Europe-based alternative protein company. The project will begin using existing 100 KL capacity (Phase 0) before expanding to a 750 KL facility (Phase 1) and potentially beyond (Phase 2). The company also has a 10-year take-or-pay contract with a US-based alternative protein company (commercial batches expected Q1 FY28) and a 5-year take-or-pay contract for insulin drug substance (commissioning expected Q4 FY27, sales mid-FY28).
  • Classical Fermentation APIs: Two products have been commercialized for the Indian market, with 6 more in the pipeline. A long-term goal is to develop proprietary products using synthetic biology.
  • Vegan Vitamin D3: The plant is under construction and qualification is expected by end of FY27. Sales to nutraceutical/veterinary markets are expected to begin early next fiscal year (FY28).
  • Guidance: Management maintained its FY27 outlook of approximately 20% revenue growth and around 25% EBITDA growth, with a range of 5% points either side.

Additional Notes Section

  • The document is the enclosed transcript of the earnings call, submitted as a regulatory filing pursuant to SEBI LODR Regulations.
  • Financial data was disclosed and discussed in detail during the call, as summarized above.
  • Logistical details like dial-in numbers were not included in the transcript.